Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Derivatives of M that possess either an
2024-01-13

Derivatives of (+)-M100907 that possess either an alkyne or an azide have been synthesized. The most active enantiomer was obtained by resolution of a relatively early intermediate in the synthesis. The ability of these BV6 to maintain 5-HTR antagonist properties as (+)-M100907 was demonstrated toge
acetylcholine chloride synthesis br Experimental procedure b
2024-01-13

Experimental procedure Introduction Migraine is a debilitating neurovascular disorder characterized by recurring unilateral pulsating headaches of moderate to severe intensity, associated with nausea, photophobia and/or phonophobia, lasting from 4 to 72 h (Headache Classification Committee of
At present drugs that specifically inhibit
2024-01-13

At present, drugs that specifically inhibit YAP activity are not available. In fact, verteporfin, which was originally described as a specific inhibitor of YAP-TEAD interaction, has been recently shown to exert its activity through selective induction of proteotoxicity rather than through YAP inhibi
br Materials and Methods br
2024-01-13

Materials and Methods Author Contributions Conflicts of Interest Acknowledgments This study was funded by the NIH Common Fund (UH2TR000943) through the Office of Strategic Coordination/Office of the NIH Director, an NCI/NIH grant (1R21CA199050), the MD Anderson Cancer Center support gran
br Conflict of interest br Introduction Ovarian cancer
2024-01-13

Conflict of interest Introduction Ovarian cancer is the most lethal gynecological malignancy, and ranks as the fifth leading cause of cancer death among women. The American Cancer Society estimates that about 22,280 new ovarian cancer cases and 14,240 deaths will occur in the United States in
and LO are members of
2024-01-13

5- and 12/15-LO are members of the lipoxygenase family that convert arachidonic UNC 3230 into lipid mediators such as leukotriene B4 (LTB) and 12()-hydroxyeicosatetraenoic acid (HETE) and 15()-HETE, respectively. Evidence from several in vitro and in vivo studies has shown that activation of the 5-
br Perspective AA LA and other PUFAs and
2024-01-13

Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path
In the nineties we knew that
2024-01-13

In the nineties we knew that (-)baclofen was the stereo-selective ligand for the GABAB receptor which had been recognised by Norman Bowery as a receptor for GABA, which was different from the GABAA receptor (Hill and Bowery, 1981). GABAB receptor antagonists were also synthesised and made available
br Introduction Heart failure HF is a
2024-01-12

Introduction Heart failure (HF) is a chronically progressive disease and one of the most important causes of morbidity and mortality worldwide despite recent improvements in its treatment [1], [2], [3]. The mortality and morbidity benefits of angiotensin converting enzyme inhibitor (ACEI) are wel
No starting dose adjustment is
2024-01-12

No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad
In the present study a splice acceptor site
2024-01-12

In the present study, a splice acceptor site mutation (c.1769-1G > C) was identified in AR gene from patients with CAIS. The c.1769-1G > C mutation results in replacement of the normal sequence (CAG/G) with a new sequence (CAC/G) at the splice acceptor site of intron 2. In the splice acceptor site r
br Conclusions In summary we report a novel preliminary find
2024-01-12

Conclusions In summary, we report a novel preliminary finding of a potential racial difference in the association of Cd-content and AR expression in prostate cancer that will need to be confirmed in larger studies. Although the association of Cd and AR protein expression is not strong in tumor ti
Our in vitro data show that CyaA does
2024-01-12

Our in vitro data show that CyaA does not play a critical role in the bacterial adherence to mammalian cells. This observation is in contrast to previous studies that reported a role for CyaA in FHA-mediated adherence of B. pertussis bacteria to the respiratory epithelial Iodoacetyl-LC-Biotin [37,3
HS-173 Although the immobilization by histidine tag exhibits
2024-01-12

Although the immobilization by histidine tag exhibits effectiveness in oriented enzyme immobilization, it still faces some challenges [31]. On one hand, some unnecessary metal-binding proteins that interfere with the combination between the target protein and the supports or the additional interacti
br Results br Discussion Utilizing a
2024-01-12

Results Discussion Utilizing a proteomic approach, we identified HSP90β as a protein that becomes associated with surface AChR in agrin-stimulated muscle cells. We demonstrate that HSP90β does not interact with the AChR directly; instead, via direct interaction with rapsyn, HSP90β becomes asso
8834 records 256/589 page Previous Next First page 上5页 256257258259260 下5页 Last page